129 related articles for article (PubMed ID: 8714272)
21. Antileukemic effects of rapid cyclosporin withdrawal in patients with relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation.
Brandenburg U; Gottlieb D; Bradstock K
Leuk Lymphoma; 1998 Nov; 31(5-6):545-50. PubMed ID: 9922044
[TBL] [Abstract][Full Text] [Related]
22. Predicting relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation by bcr-abl mRNA and DNA fingerprinting.
Okamoto R; Harano H; Matsuzaki M; Motomura S; Maruta A; Kodama F; Mohri H; Okubo T
Am J Clin Pathol; 1995 Nov; 104(5):510-6. PubMed ID: 7572810
[TBL] [Abstract][Full Text] [Related]
23. Graft failure after donor leucocyte infusion in relapsed chronic myeloid leukaemia: successful treatment with cyclophosphamide and antithymocyte globulin followed by peripheral blood stem cell infusion.
Keil F; Kalhs P; Haas OA; Fritsch G; Mitterbauer G; Brugger S; Lechner K; Schwarzinger I; Mannhalter C; Linkesch W; Kurz M; Greinix HT
Br J Haematol; 1996 Jul; 94(1):120-2. PubMed ID: 8757519
[TBL] [Abstract][Full Text] [Related]
24. Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation. EBMT Immunology and Chronic Leukemia Working Parties.
Kolb HJ
Vox Sang; 1998; 74 Suppl 2():321-9. PubMed ID: 9704463
[TBL] [Abstract][Full Text] [Related]
25. A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society.
Espérou H; Boiron JM; Cayuela JM; Blanchet O; Kuentz M; Jouet JP; Milpied N; Cahn JY; Faucher C; Bourhis JH; Michallet M; Tanguy ML; Vernant JP; Gabert J; Bordigoni P; Ifrah N; Baruchel A; Dombret H;
Bone Marrow Transplant; 2003 May; 31(10):909-18. PubMed ID: 12748668
[TBL] [Abstract][Full Text] [Related]
26. Unrelated donor leukocyte infusions to treat relapse after unrelated donor bone marrow transplantation.
Leis J; Porter DL
Leuk Lymphoma; 2002 Jan; 43(1):9-17. PubMed ID: 11908741
[TBL] [Abstract][Full Text] [Related]
27. [Successful treatment of recurrent chronic myelogenous leukemia in allogeneic marrow transplant recipient with the donor leukocyte transfusion, without induction of acute graft-versus-host disease].
Yamazaki H; Nakao S; Takamatsu H; Ito T; Ueda M; Shiobara S; Matsuda T
Rinsho Ketsueki; 1995 Jul; 36(7):677-81. PubMed ID: 7563596
[TBL] [Abstract][Full Text] [Related]
28. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
[TBL] [Abstract][Full Text] [Related]
29. [Donor leukocyte transfusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation].
Itoh T; Hatta Y; Miyajima T; Simojima H; Sawada U; Horie T
Rinsho Ketsueki; 1998 Jun; 39(6):409-15. PubMed ID: 9695667
[TBL] [Abstract][Full Text] [Related]
30. In relapsed patients after lymphocyte depleted bone marrow transplantation the percentage of donor T lymphocytes correlates well with the outcome of donor leukocyte infusion.
Schattenberg A; Schaap N; Van De Wiel-Van Kemenade E; Bär B; Preijers F; Van Der Maazen R; Roovers E; De Witte T
Leuk Lymphoma; 1999 Jan; 32(3-4):317-25. PubMed ID: 10037029
[TBL] [Abstract][Full Text] [Related]
31. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
32. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
Pichert G; Roy DC; Gonin R; Alyea EP; Bélanger R; Gyger M; Perreault C; Bonny Y; Lerra I; Murray C
J Clin Oncol; 1995 Jul; 13(7):1704-13. PubMed ID: 7602361
[TBL] [Abstract][Full Text] [Related]
33. Graft-versus-host disease following second syngeneic stem cell transplantation for relapsed chronic myeloid leukemia.
Reiter E; Greinix HT; Mitterbauer G; Fischer G; Keil F; Mannhalter C; Rabitsch W; Schwarzinger I; Worel N; Lechner K; Kalhs P
Ann Hematol; 1998 Dec; 77(6):283-6. PubMed ID: 9875666
[TBL] [Abstract][Full Text] [Related]
34. Transfusion of donor buffy coat cells in the treatment of persistent or recurrent malignancy after allogeneic bone marrow transplantation.
Collins RH; Pineiro LA; Nemunaitis JJ; Jain VK; Waxman D; Miller WV; Fay JW
Transfusion; 1995; 35(11):891-8. PubMed ID: 8604484
[TBL] [Abstract][Full Text] [Related]
35. [Rapid recovery of hemopoiesis and alleviation of symptoms similar to peri-engraftment syndrome after donor leukocyte infusion].
Azuma T; Hara M; Kojima K; Nawa Y
Rinsho Ketsueki; 1999 Jan; 40(1):59-62. PubMed ID: 10067099
[TBL] [Abstract][Full Text] [Related]
36. New donor leukocyte approaches may improve outcomes in relapsed CML post-transplant.
Oncology (Williston Park); 1996 Sep; 10(9):1380. PubMed ID: 8882927
[No Abstract] [Full Text] [Related]
37. [Treatment of leukemia relapsed after allogenic bone marrow transplantation with donor lymphocyte infusion: report of 11 cases].
Sanz Rodríguez C; Steegmann JL; Granda A; de la Cámara R; Figuera A; Arranz R; Gómez-García de Soria V; Alegre A; Fernández-Rañada JM
Sangre (Barc); 1999 Dec; 44(6):456-63. PubMed ID: 10822760
[TBL] [Abstract][Full Text] [Related]
38. [Donor leukocyte transfusion in a patient with relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation: analysis of natural killer cell activity and T-cell receptor repertoire in bone marrow T cells that exhibited graft-versus-leukemia activity].
Suehiro Y; Muta K; Umemura T; Motomura S; Nishimura J; Nawata H; Kimura N
Rinsho Ketsueki; 1999 Jan; 40(1):40-5. PubMed ID: 10067095
[TBL] [Abstract][Full Text] [Related]
39. Donor leukocyte infusions.
Mackinnon S
Baillieres Clin Haematol; 1997 Jun; 10(2):357-67. PubMed ID: 9376669
[TBL] [Abstract][Full Text] [Related]
40. Activated allogeneic cell therapy (allo-ACT) for relapsed chronic myelogenous leukemia (CML) refractory to buffy coat transfusions post-allogeneic bone marrow transplantation.
Kapelushnik J; Nagler A; Or R; Naparstek E; Ackerstein A; Samuel S; Morecki S; Nabet C; Slavin S
Bone Marrow Transplant; 1996 Dec; 18(6):1153-6. PubMed ID: 8971387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
